OncNGS

▶️ We’re very happy to share this video as the project comes to an end, with partners reflecting on a shared journey and what we’ve built together, showing how we helped advance next-generation sequencing in oncology across Europe! youtu.be/cz7lY4dqUbw

Rossana Alessandrello, Value Based Procurement Director at #AQuAS, has participated at the @oncNGS final event to explore the future of #innovation procurement in precision cancer diagnostics 💡

@Agilent @KU_Leuven @OncoDNA @AlleConCancro @AQuAScat @carmen_laplaza @EUScienceInnov The event concluded with a very interesting roundtable discussion, on how innovation procurement can accelerate the adoption of precision diagnostics in healthcare systems.

@Agilent @KU_Leuven @OncoDNA @AlleConCancro @AQuAScat "Close collaboration between healthcare and industry increases speed of innovation. Pre-Commercial Procurement allows a much better match between the real clinical needs and the final product." 💬@carmen_laplaza (@EUScienceInnov).

oncNGS final event has just started! After 6 years of collaboration, 14 partners from 5 European countries conclude a Pre-Commercial Procurement (PCP) developing affordable next-generation sequencing (#NGS)-based testing solutions for #oncology. Follow the event below! 🧵

📣 Join us on 10 April in Brussels for the oncNGS final event Discover the project’s results and discuss how innovation procurement can support the adoption of precision cancer diagnostics. 🕙 10:00–16:00 📍 Brussels ➡️ oncngs.eu/index.php/2026…

We were glad to have oncNGS showcased on a poster at the occasion of the EUnetCCC (The European Network of Comprehensive Cancer Centres) annual meeting in Paris, last week. The poster was presented by oncNGS project manager, Gordana Raicevic Toungouz (@Sciensano).

Our goal is to improve #cancer care by making advanced and accurate diagnostic tools more accessible and impactful. Read the full paper to learn more about our journey and key achievements.

We are thrilled to announce the publication of our paper on the oncNGS PCP project in @ESMO_Open! It showcases our innovative approach to drive the development of new Liquid Biopsy #NGS (Next Generation Sequencing) #cancer tests. 👉 esmoopen.com/article/S2059-…

🔴 OncNGS enters Phase 3 of the PCP with 2 innovative solutions for #cancer #NGS testing! Following a comprehensive evaluation, @Agilent and @KU_Leuven will now demonstrate clinical, technical, financial, and commercial feasibility of their solutions. 👉 oncngs.eu/index.php/2025…

Fruitful face-to-face @oncNGS consortium meeting today at @sciensano in Brussels, in order to assess the interim outcome reports describing current advancement of the prototype development of the three contractors of the oncNGS PCP phase 2.